Stockscreener 앱 받기
4.205
1.29%
-0.055
전일 마감가:
$4.26
열려 있는:
$4.25
하루 거래량:
36,651
Relative Volume:
0.20
시가총액:
$254.20M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.2991
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
-15.90%
1개월 성능:
-12.40%
6개월 성능:
-10.15%
1년 성능:
-17.39%
1일 변동 폭
$4.145
$4.425
1주일 범위
$4.125
$5.0346
52주 변동 폭
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.25 | 254.80M | 45.15M | -39.23M | -18.93M | -1.829 |
|
ABT
Abbott Laboratories
|
110.21 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
343.04 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.00 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.86 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.64 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus Life Sciences Signals Confident Growth Path - TipRanks
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
Research Analysts Issue Forecasts for TLSI Q1 Earnings - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - Defense World
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - MarketBeat
Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings - Investing.com
TriSalus Life Sciences Q4 Earnings Call Highlights - Yahoo Finance
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio - MSN
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise - Investing.com
TriSalus (TLSI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance - Bluefield Daily Telegraph
Earnings Summary: TriSalus Life Sciences Q4 - Benzinga
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Exploring TriSalus Life Sciences's Earnings Expectations - Benzinga
Northland Securities Forecasts TLSI FY2025 Earnings - MarketBeat
TLSIW Stock Price, News & Analysis - Stock Titan
TriSalus Life Sciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
TLSI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TriSalus to Raise $40M from Stock Sale - National Today
TLSIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Surge: What are TriSalus Life Sciences Inc Equity Warrants growth levers2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
TriSalus Life Sciences (TLSI) to Release Earnings on Thursday - MarketBeat
TLSI PE Ratio & Valuation, Is TLSI Overvalued - Intellectia AI
TriSalus Life Sciences (NASDAQ: TLSI) raises ~$40M in 9.76M-share offering - Stock Titan
Cancer-focused medtech company TriSalus sets March 5 call on 2025 results - Stock Titan
TriSalus prices $40 mln public stock offering - MSN
TLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Buying: David Patience Acquires Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus
TLSI | TriSalus Life Sciences, Inc. Insider Trading - Quiver Quantitative
TLSI | TriSalus Life Sciences, Inc. FinancialsIncome Statement - Quiver Quantitative
TriSalus Life Sciences (TLSI) CFO adds 3,657 shares in open-market buy - Stock Titan
TriSalus director Gary Gordon buys 9,756 shares (TLSI) in open market - Stock Titan
Director William Valle adds 30,487 TriSalus (TLSI) shares - Stock Titan
TriSalus Life Sciences (TLSI) CEO purchases 30,487 common shares - Stock Titan
TriSalus Life Sciences (TLSI) director adds 361,098 shares in open-market buys - Stock Titan
TriSalus Life Sciences announces plans for public offering - Medical Buyer
TriSalus prices $40M public offering at $4.10 per share By Investing.com - Investing.com South Africa
TriSalus Life Sciences Prices Underwritten Public Equity Offering - TipRanks
TriSalus (TLSI) to raise about $40M in underwritten stock sale - Stock Titan
TriSalus to raise $40M from stock sale - BizWest
TriSalus Life Sciences Prices Stock Offering at $4.10 a Share - marketscreener.com
TriSalus prices $40M public offering at $4.10 per share - Investing.com
Cancer-focused medical tech firm TriSalus raises $40M at $4.10 a share - Stock Titan
Cancer-focused TriSalus Life Sciences plans new stock sale - Stock Titan
Volume Summary: How does TriSalus Life Sciences Inc score in quality rankings2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Risk Hedge: What is TriSalus Life Sciences Inc Equity Warrants P E ratio telling usJuly 2025 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Will TriSalus Life Sciences Inc. benefit from rate cutsEarnings Miss & AI Enhanced Market Trend Forecasts - mfd.ru
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
1.47%
자본화:
|
볼륨(24시간):